Show simple item record

dc.contributor.authorSánchez Peña, Enric
dc.contributor.authorMizab, Chadia
dc.contributor.authorSauret, Ariadna
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorMartí, Raquel
dc.contributor.authorLópez Cano, Carolina
dc.contributor.authorHernández García, Marta
dc.contributor.authorGutiérrez Carrasquilla, Liliana
dc.contributor.authorCarmona, Paola
dc.contributor.authorGonzález, Jessica
dc.contributor.authorDalmases, Mireia
dc.contributor.authorHernández, Cristina
dc.contributor.authorSimó, Rafael
dc.contributor.authorLecube Torelló, Albert
dc.description.abstractIn order to compare spirometric maneuvers in adults according to the presence of type 1 diabetes, a case-control study including 75 patients with type 1 diabetes and 75 controls matched by sex, age, and body mass index were designed. In addition, 75 patients with type 1 diabetes were added to examine the potential the impact of subcutaneous insulin therapy on pulmonary function. Lung function measurements were assessed according to the global initiative for chronic obstructive lung disease guidelines. Basal insulin included long-acting insulin analogues and the delivered background insulin in patients with pump therapy. Bolus insulin included rapid-acting insulin analogues and the delivered insulin to cover postprandial hyperglycemias. Patients with type 1 diabetes showed lower spirometric values in comparison to the control group, together with a higher prevalence of forced expiratory volume in the first second (FEV1) <80% (10.7% vs. 2.7%, p = 0.044) and restrictive ventilatory pattern (10.7% vs. 0%, p = 0.006) The dose of basal insulin (U/kg/day) showed a negative correlation with forced vital capacity (FVC) (r = −0.205, p = 0.012) and FEV1 (r = −0.182, p = 0.026). The optimal cut-off value for identifying patients with a restrictive spirometric pattern was 0.5 U/kg/day of basal insulin. Additionally, basal insulin (U/kg/day) independently predicted the presence of both a restrictive spirometric pattern (OR = 77.1 (3.2 to 1816.6), p = 0.007) and an abnormal FEV1 (OR = 29.9 (1.5 to 562.8), p = 0.023). In patients with type 1 diabetes, higher basal insulin dosage seems to be related with an impairment of pulmonary function.ca_ES
dc.description.sponsorshipThis work was partially supported by grants from the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria PI12/00803, PI15/00260 and PI18/00964), and European Union (European Regional Development Fund, Fondo Europeo de Desarrollo Regional, “Una manera de hacer Europa”), and Menarini Spain S-A. CIBER de Diabetes y Enfermedades Metabólicas Asociadas and CIBER de Enfermedades Respiratorias are initiatives of the Instituto de Salud Carlos III. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.ca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, núm. 5, p. 1249ca_ES
dc.rightscc-by (c) Sánchez Peña, Enricca_ES
dc.subjectBasal insulinca_ES
dc.subjectBolus insulinca_ES
dc.subjectLung functionca_ES
dc.subjectType 1 diabetesca_ES
dc.titleEffect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Studyca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Sánchez Peña, Enric
Except where otherwise noted, this item's license is described as cc-by (c) Sánchez Peña, Enric